◆ Market Terminal AILook up a stock

Parabilis Medicines, Inc. (PBLS)

Healthcare · Biotechnology · Mid-cap · updated October 16, 2026

NOT A BUY TODAY
What this means. Parabilis Medicines, Inc. is an average business by our measures, its shares look fairly priced, and its share price has been weak.
Value44
Quality43
Price trend4
Overall36
2549 of 2764rank among the US stocks we score (our core model buys the top 15)
8%of US stocks we score rank below it

Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.

Insider trades, last 90 days

1 insider bought $6.9M on the open market.

Ra Capital Management, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M.Director; Director · 10% ownerBoughtJul 2247,250 shat $29.77 · $1.4M
Ra Capital Management, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M.Director; Director · 10% ownerBoughtJul 2165,923 shat $29.25 · $1.9M
Ra Capital Management, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M.Director; Director · 10% ownerBoughtJul 20131,420 shat $27.28 · $3.6M

From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.

Higher-scoring in the same industry

Interactive lookupGet the Ledger every Monday

Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy